| Revenue growth | 10% YoY overall; 17% in Biopharmaceuticals; 16% in Biosimilars. |
|---|---|
| Margins | EBITDA 21%; Biosimilars 25%; Generics improved to 7%. |
| Demand visibility | Strong for insulins and new biosimilar launches in North America. |
| Management confidence | High; integration phase complete; focusing on profitable growth over market share. |
Growth
Biosimilars revenue rose 16% YoY; Generics grew 21%. Net profit saw massive recovery due to lower interest costs.
Outlook
Expect momentum acceleration in H2 FY27; Syngene revenue degrowth in FY27; aim for margin expansion and debt reduction.
Risks
Syngene faces temporary decline from key client; net debt increased by INR 1,100 Cr due to inventory stocking.
Last quarter's promises, checked
Delivered
- Guided Biosimilars growth → delivered 16% YoY (= BEAT)
- Guided interest cost reduction → delivered 23% YoY reduction (= BEAT)
- Guided US Aflibercept launch in H2 → delivered launch on schedule (= BEAT)
Partly delivered
- Guided margin expansion → delivered 21% group margin vs 22% FY26 base (= PARTIAL)
Missed
- Guided debt reduction priority → delivered INR 1,100 Cr net debt increase (= MISS)
- Guided Syngene stable performance → delivered 16% revenue decline (= MISS)
Investor Presentation filed with BSE, NSE: BIOCON. Summary written with AI assistance from the document.
Biocon Ltd: key numbers
- Share price
- ₹382.15
- Market cap
- ₹62,279 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 125.7×Sector 50.4×
- Promoter holding
- 44.68%-0.23% QoQ
- FII holding
- 8.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Business Update
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Biocon Bags New Order from Bahiafarma and Bionovis
Biocon secured a 10-year supply contract for Pertuzumab in Brazil under a government program. The partnership involves milestone payments and revenue sharing for the company.
- From
- Bahiafarma and Bionovis (Brazil PDP program)
- Execution
- 10 years
Biocon Investor Presentation: Key Takeaways
Biocon reported Q1 FY27 revenue of ₹4,336 Cr (up 10% YoY) and Net Profit (before exceptional) of ₹145 Cr (up 245% YoY). Strategy focuses on North American biosimilar launches and generic margin expansion.
Biocon Q1 FY27 Results: Net Profit ₹136.8 Cr, Up 53.4% YoY
Biocon Ltd reported revenue from operations of ₹4,336 Cr (+10.0% YoY) and net profit of ₹136.8 Cr (+53.4% YoY) for Q1 FY27.
- Key figure
- Net profit ₹136.8 Cr · +53.4% YoY
Biocon Earnings Call: Key Takeaways
Biocon's June 2026 presentation highlights its transformation into an integrated biopharma leader following the Viatris acquisition. FY26 revenue reached $1,924M (₹16,927 Cr) with a 22% EBITDA margin.
Biocon Earnings Call: Key Takeaways
Biocon Q4 FY26 reported 10% YoY revenue growth (ex-lenalidomide) with integration of biosimilars/generics complete. Focus shifts to execution and deleveraging.